GlassScriptPhysician profile
Richard J Bearoff
NPI 1336477884
$2,574.05
in general payments reported to CMS, 2019-2025
29 companies · $631 in 2025
The $631 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $57.90 · 2021: $365 · 2022: $331 · 2023: $481 · 2024: $442 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,554.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $601.64 | 2019-2025 | Qulipta, Ubrelvy |
| Pfizer INC. | $594.44 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $143.55 | 2019-2024 | Airsupra |
| Exact Sciences Corporation | $134.22 | 2023-2025 | Cologuard Collection Kit |
| Tolmar, INC. | $132.96 | 2023-2025 | Jatenzo |
| Merck Sharp & Dohme LLC | $127.78 | 2019-2025 | Lagevrio, Capvaxive, Gardasil |
| Glaxosmithkline, LLC. | $90.47 | 2019-2024 | Shingrix |
| Amgen INC. | $84.69 | 2022-2024 | Otezla, Repatha |
| Eisai INC. | $78.77 | 2020-2024 | |
| Novo Nordisk INC | $60.01 | 2023-2025 | Ozempic, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $57.87 | 2021 | |
| Idorsia Pharmaceuticals US INC | $50.70 | 2022-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $37.80 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $37.48 | 2022 | |
| Lilly USA, LLC | $37.22 | 2024 | Mounjaro |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $33.14 | 2022-2023 | Gralise |
| Boston Scientific Corporation | $32.57 | 2020-2023 | Bodyguardian |
| Shire North American Group INC | $31.32 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.96 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $21.11 | 2019 | |
| Amarin Pharma, INC. | $20.72 | 2019 | |
| Alexion Pharmaceuticals, INC. | $20.65 | 2024 | Ultomiris |
| Fidia Pharma USA INC. | $20.48 | 2023 | Hymovis |
| Vbi Vaccine (Delaware) INC. | $17.90 | 2023 | Prehevbrio |
| Astellas Pharma US INC | $17.63 | 2019 | |
| Clarus Therapeutics INC. | $17.30 | 2021 | |
| Nalu Medical, INC. | $16.96 | 2025 | Nalu Neurostimulation System |
| Currax Pharmaceuticals LLC | $14.36 | 2025 | Contrave |
| Linus Health, INC. | $14.35 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Bearoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.